Tocilizumabfor polymyalgia rheumatica and giant cell arteritis

Download in PDF

Tocilizumab is a monoclonal antibody that blocks interleukin-6 pathway of inflammation. Clinicaltrialsestablishedthefollowing preliminary indications for tocilizumab therapy in polymyalgia rheumatica and giant cell arteritis: as a first line in patients with severe comorbidity for rapid tapering of corticosteroids and as a second line in patients refractory to or intolerant of metothrexate or with recurrent course of disease.

Key words

Polymyalgia rheumatica, giant cell arteritis, treatment, tocilizumab.